8/9/2019 anthracimycin
3/4
Documento 1 de 1
MRSA; Findings from Trius Therapeutics Update Understanding of
Methicillin-Resistant
Staphylococcus aureus Anthracimycin activity against
contemporary methicillin-resistant
Staphylococcus aureus)
Enlace de documentos de ProQuest
Resumen: The news reporters obtained a quote from the research
from Trius Therapeutics, "All strains of S.
aureus tested, including methicillin-susceptible,
methicillin-resistant (MRSA) and vancomycin-resistant strains
of
S. aureus, were susceptible to anthracimycin at MIC values of
4-log kill of USA300
MRSA within 3 h at five times its MIC. At concentrations
significantly below the MIC, anthracimycin slowed
MRSA growth and potentiated the bactericidal activity of the
human cathelicidin, LL-37. The bactericidal activity
of anthracimycin was somewhat mitigated in the presence of 20%
human serum, and the compound was
minimally toxic to human cells, with an IC50 (inhibitory
concentration 50)=70 mg l(-1) against human carcinoma
cells.
Texto completo: 2014 OCT 1 (NewsRx) -- By a News Reporter-Staff
News Editor at Biotech Week -- Data
detailed on MRSA have been presented. According to news
reporting originating in San Diego, California, by
NewsRx journalists, research stated, "Anthracimycin is a
recently discovered novel marine-derived compound
with activity against Bacillus anthracis. We tested
anthracimycin against an expanded panel of Staphylococcus
aureus strains in vitro and in vivo."
The news reporters obtained a quote from the research from Trius
Therapeutics, "All strains of S. aureus tested,
including methicillin-susceptible, methicillin-resistant (MRSA)
and vancomycin-resistant strains of S. aureus,
were susceptible to anthracimycin at MIC values of 4-log kill of
USA300 MRSA within
3 h at five times its MIC. At concentrations significantly below
the MIC, anthracimycin slowed MRSA growth and
potentiated the bactericidal activity of the human cathelicidin,
LL-37. The bactericidal activity of anthracimycin
was somewhat mitigated in the presence of 20% human serum, and
the compound was minimally toxic to
human cells, with an IC50 (inhibitory concentration 50)=70 mg
l(-1) against human carcinoma cells. At
concentrations near the MIC, anthracimycin inhibited S. aureus
nucleic acid synthesis as determined by
optimized macromolecular synthesis methodology, with inhibition
of DNA and RNA synthesis occurring in the
absence of DNA intercalation. Anthracimycin at a single dose of
1 or 10 mg kg(-1) was able to protect mice from
MRSA-induced mortality in a murine peritonitis model of
infection."
According to the news reporters, the research concluded:
"Anthracimycin provides an interesting new scaffoldfor future
development of a novel MRSA antibiotic."
For more information on this research see: Anthracimycin
activity against contemporary methicillin-resistant
Staphylococcus aureus. Journal of Antibiotics,
2014;67(8):549-553. Journal of Antibiotics can be contacted at:
Japan Antibiotics Research Assoc, 2 20 8 Kamiosaki Shinagawa Ku,
Tokyo, 141, Japan. (Nature Publishing
Group - www.nature.com/; Journal of Antibiotics -
www.nature.com/ja/)
Our news correspondents report that additional information may
be obtained by contacting M.E. Hensler, Trius
Therapeut, San Diego, CA, United States. Additional authors for
this research include K.H. Jang, W.
Thienphrapa, L. Vuong, D.N. Tran, E. Soubih, L. Lin, N.M. Haste,
M.L. Cunningham, B.P. Kwan, K.J. Shaw, W.
Fenical and V. Nizet.
Keywords for this news article include: MRSA, Amides, San Diego,
California, Bacillales, United States, Drug
Resistance, Organic Chemicals, Staphylococcaceae, Gram-Positive
Cocci, Penicillin Resistance, Gram-Positive
Bacteria, Methicillin Resistance, beta-Lactam Resistance,
Beta-Lactam Antibiotics, North and Central America,
18 January 2015 Page 1 of 2 ProQuest
http://search.proquest.com/docview/1564411359?accountid=139608http://search.proquest.com/docview/1564411359?accountid=139608
8/9/2019 anthracimycin
4/4
Endospore-Forming Bacteria
Our reports deliver fact-based news of research and discoveries
from around the world. Copyright 2014,
NewsRx LLC
Ttulo: MRSA; Findings from Trius Therapeutics Update
Understanding of Methicillin-Resistant Staphylococcus
aureus (Anthracimycin activity against contemporary
methicillin-resistant Staphylococcus aureus)
Ttulo de publicacin:
Biotech Week
Primera pgina: 102
Ao de publicacin: 2014
Fecha de publicacin: Oct 1, 2014
Ao: 2014
Editorial: NewsRx
Lugar de publicacin:Atlanta
Pas de publicacin:
United States
Materia de publicacin: Medical Sciences--Computer
Applications
ISSN: 15352757
Tipo de fuente: Trade Journals
Idioma de la publicacin: English
Tipo de documento: Expanded Reporting
ID del documento de ProQuest: 1564411359
URL del documento:
http://search.proquest.com/docview/1564411359?accountid=139608
Copyright: Copyright 2014, NewsRx LLC
ltima actualizacin: 2014-09-24
Base de datos: ProQuest Entrepreneurship
_______________________________________________________________
Contactar con ProQuest
Copyright2015 ProQuest LLC. Reservados todos los derechos. -
Trminos y condiciones
18 January 2015 Page 2 of 2 ProQuest
http://search.proquest.com/docview/1564411359?accountid=139608http://www.proquest.com/go/contactsupporthttp://www.proquest.com/go/contactsupporthttp://search.proquest.com/info/termsAndConditionshttp://search.proquest.com/info/termsAndConditionshttp://www.proquest.com/go/contactsupporthttp://search.proquest.com/docview/1564411359?accountid=139608
